Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$0.98 USD
+0.03 (3.53%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.99 +0.01 (0.57%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LCTX 0.98 +0.03(3.53%)
Will LCTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LCTX
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Brookdale Senior Living (BKD) Reports Q2 Loss, Misses Revenue Estimates
LCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for LCTX
LCTX: Analyst Jason Kolbert from D. Boral Capital Maintains Buy Rating | LCTX Stock News
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business ...
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and ...
Lineage Cell Therapeutics doses first patient in DOSED study
BlackRock, Inc. Significantly Reduces Holdings in Lineage Cell Therapeutics Inc